GLP-1 Insurance Coverage in 2026: Medicare, Medicaid, Employer Plans, the November 2025 Pricing Deals and TrumpRx, Explained

Five doors, five prices

The same milligram of tirzepatide costs a different amount depending on which door a patient walks through: an employer plan with coverage, an employer plan without it, Medicare, Medicaid, or a cash-pay channel, which is itself several doors (manufacturer direct, TrumpRx, or compounded telehealth). This guide walks through each as of our last review. Coverage rules changed substantially in late 2025 and may have changed again; treat every figure here as a starting point to confirm with the plan or channel itself.

Commercial insurance

Most Americans under 65 with coverage get it through an employer, and employers decide whether the plan covers anti-obesity medications. In 2024 and 2025, as GLP-1 spending rose, a significant share of employers dropped or restricted weight-management coverage; others kept it with tighter rules. A plan that covers Zepbound or Wegovy for weight management almost always requires prior authorization, typically a BMI of 30 or higher (or 27 with a comorbidity), documentation of a lifestyle program, and sometimes step therapy through an older drug. Some plans require continued weight loss to renew. Pharmacy benefit managers also steer between the two drugs: in July 2025 CVS Caremark made Wegovy its preferred GLP-1 for weight management and removed Zepbound from its standard formulary, and other PBMs made their own choices, so a patient may be covered for one drug and not the other.

Where coverage exists, the manufacturers' savings cards do the rest. Lilly's Zepbound card reduces the copay to as little as $25 per month for commercially insured patients with coverage; Novo's Wegovy offer works similarly. Without coverage, the cards offer much less, and the direct channels below are the relevant price. Medicare and Medicaid patients are excluded from savings cards by law.

The practical steps: call the plan (not the provider) and ask whether Zepbound and Wegovy are covered for weight management, what the prior-authorization criteria are, and what the copay is at each tier; then ask the prescriber's office to submit the authorization with the documentation the plan lists. Telehealth providers that specialize in this, such as Ro and Calibrate, exist because the paperwork is real work.

Medicare

Federal law has long excluded drugs for weight loss from Part D. Coverage arrived through the side door of other indications: since 2024, Part D plans may cover Wegovy for reducing cardiovascular risk in adults with established cardiovascular disease and obesity or overweight, following the SELECT trial and the 2024 label change; since 2025, they may cover Zepbound for obstructive sleep apnea in adults with obesity, following SURMOUNT-OSA. A beneficiary who meets either indication can be covered; a beneficiary who wants the drug for weight alone historically could not.

The November 2025 agreements between the administration and both manufacturers changed the announced landscape. Under them, Medicare would pay $245 per month for Wegovy and Zepbound, and eligible beneficiaries would pay a $50 copay, under a coverage pathway for obesity with clinical criteria (the announcements referenced BMI thresholds with comorbidities), scheduled to begin in 2026, with Medicaid access at the same price for states that opt in. Whether and how that pathway is operating by the time you read this depends on implementation; ask the Part D plan directly and check the Medicare.gov formulary tool. Part D plans also negotiate their own formularies, so coverage under an indication is not automatic.

Medicaid

Medicaid coverage of GLP-1s for obesity is decided state by state. As of 2025 roughly a dozen to sixteen states covered them for weight management, with varying prior-authorization rules, and several had restricted or dropped coverage because of cost. Coverage for diabetes (Ozempic, Mounjaro) is near-universal. The November 2025 agreements offered states the $245 price for obesity coverage; uptake is a state decision. Our state pages note where coverage existed at last review, and a Medicaid beneficiary should confirm with the state program.

The direct channels

LillyDirect. Lilly sells Zepbound single-dose vials to self-pay patients with a prescription. After the November 2025 cuts, the lowest dose was announced at about $299 per month and higher doses at about $449, down from $349 to $499 earlier in 2025 and $399 to $549 at the 2024 launch. Pens through pharmacies are priced higher.

NovoCare Pharmacy. Novo's direct channel for Wegovy pens, cut in 2025 to a flat price across doses (announced at $349 per month in early 2025, with further reductions and an introductory offer under the November agreements) and, from its approval in December 2025, oral Wegovy at a launch price for the lowest dose.

TrumpRx. The federal direct-purchase site announced in November 2025 and scheduled to launch in early 2026 listed Wegovy and Zepbound starting doses at $350 per month, described as falling toward $245 over time, and oral products, once approved, at $149 for the lowest dose. Higher doses remained through the manufacturers' channels. These are cash prices with a prescription, not insurance.

We carry the LillyDirect and NovoCare figures in the pricing database as brand benchmarks marked unverified pending our next direct check, because they changed twice in 2025 and the direct channels are the figures most likely to be out of date on any comparison site, including this one.

Where compounded medication fits

For a patient with coverage, it does not fit; a $25 to $150 copay for the approved product beats any cash price. For a patient without coverage, the comparison is between brand self-pay at roughly $245 to $449 per month (starting to maintenance doses, depending on channel and timing) and compounded telehealth at $139 to $169 all-in verified, or $169 to $278 reported at membership-model providers. At maintenance doses the brand channels cost roughly two to three times the cheapest compounded plan, which is why the compounded market persists after the shortage ended and why our rankings exist. The brand versus compounded article sets out what the price difference buys and costs.

A checklist before choosing a door

1. Call your plan and ask about weight-management coverage for both Zepbound and Wegovy, the prior-authorization criteria, and the copay. Write down who you spoke to.
2. If covered, get the prescription from any clinician and apply the manufacturer savings card.
3. If on Medicare, ask whether you meet the cardiovascular or sleep-apnea indication, and ask your Part D plan whether the obesity pathway announced for 2026 is active.
4. If on Medicaid, ask the state program whether it covers anti-obesity medications and on what criteria.
5. If none applies, compare brand direct channels against verified compounded prices at your expected maintenance dose over twelve months, using the true-cost calculator.
6. Recheck every six months. The 2025 changes were the largest in the market's history and the direction has been toward lower brand prices and broader public coverage.

Sources

1. Centers for Medicare & Medicaid Services. Part D coverage of anti-obesity medications for medically accepted indications: Wegovy (cardiovascular, 2024) and Zepbound (obstructive sleep apnea, 2025).
2. The White House. Announcements of pricing agreements with Eli Lilly and Novo Nordisk, November 6, 2025.
3. Eli Lilly. Zepbound Savings Card terms, 2025-2026.
4. Novo Nordisk. Wegovy Savings Offer terms and NovoCare Pharmacy pricing, 2025-2026.
5. KFF. Medicaid coverage of GLP-1s for obesity by state, 2025.
6. Lincoff AM et al. SELECT trial. N Engl J Med 2023;389:2221-2232.
7. Malhotra A et al. SURMOUNT-OSA. N Engl J Med 2024;391:1193-1205.

Citations are to primary sources (peer-reviewed trials, FDA labeling and announcements, and provider pricing pages). See our sources policy and corrections log.